tiprankstipranks
Bellicum Pharmaceuticals Appoints New CEO During Dissolution
Company Announcements

Bellicum Pharmaceuticals Appoints New CEO During Dissolution

Bellicum Pharmaceuticals (BLCM) has released an update.

Don't Miss Our Christmas Offers:

Bellicum Pharmaceuticals, Inc. is undergoing a significant transformation as it executes its liquidation and dissolution plan, leading to the resignation of all board directors except for Mr. Fair, who remains the sole director. Amidst these changes, the company appointed Dave Maggio as the new CEO, leveraging his extensive experience in financial advisory and corporate finance, particularly with small to mid-market companies. The company also extended its consulting agreement with former CEO Mr. Fair to support the transition. These strategic moves aim to navigate the dissolution process smoothly, reflecting the company’s commitment to a structured and professional approach.

For further insights into BLCM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskBellicum Pharmaceuticals Finalizes Sale and Approves Dissolution
Catie PowersBellicum Pharmaceuticals Asset Sale and Dissolution Vote Adjourned
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App